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The isothiocyanate analog (•S•2S-trans-2•is•thi•cyanat••4•5-dich••r•-N-methy••N-[2-(•-pyrr••idiny•)cyc••hexy•]ben- 
zeneacetamide, 3a)of the highly selective x-opioid receptor agonist, U50,488, was prepared as a potential site-directed 
affinity ligand for acylation of ~c-opioid receptors invivo. The isothiocyanate (3a) which we have designated UPHIT and 
its enantiomer (3b) were synthesized in 3 steps tarting from optically pure (1S,2S)-(+)-trans-2-pyrrolidinyl-N-methyl- 
cyclohexylamine (4a) and its enantiomer (4b), respectively, thus defining their absolute stereochemistry. Binding in vitro 
of the IS,2S enantiomer 3a to x receptors labelled by pH]U69,593 was shown to occur with an ICs0 value of 25.92 ___ 
0.36 nM, whereas 827.42 _ 5.88 and 115.10 + 1.23 nM were obtained for the ICso value of the IR,2R enantiomer (3b) 
and ( + )-3 respectively. Intracerebroventricular (ICV) injection of 100/zg of (_+)-3 into guinea-pig brain followed by anal- 
ysis of remaining x-binding sites 24 h later revealed that (+)-3 depleted 98% of the x receptors that bind [3H]U69,593 
and 40% of those that bind [aH]bremazocine. These preliminary data suggest exciting uses for these compounds infurther- 
ing our knowledge of the x-opioid receptor. 
Opioid agonist, ~¢-; Opioid receptor agonist, U50,488; Site-directed affinity ligand; Receptor, ~-; lntracerebroventricular administration; 
Isothiocyanate analog 
1. INTRODUCTION 
Site-directed electrophilic affinity ligands have 
been utilized with much success as tools for 
characterization of opioid receptors [1]. Efforts in 
our laboratory led to the synthesis and use of  the 
isothiocyanate-derived irreversible ligands BIT [2], 
F IT  [2] and SUPERF IT  [3] for the characteriza- 
t ion of/z- and 5-0pioid receptors. Electrophilic af- 
finity ligands such as chlornaltrexamine (CNA, a 
nitrogen mustard analog of  naltrexone) have been 
used as irreversible ligands in vivo [4]. In that 
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study [4], intracerebroventricular (ICV) injection 
of  CNA into mice resulted in long-lasting narcotic 
antagonist effects as a result of  non-selective deple- 
t ion o f  opioid receptors. In contrast, ICV injection 
of  the less reactive/5'-funaltrexamine (6'-FNA) [5] 
into rats resulted in a selective wash-resistant in- 
hibition of  /z-receptor binding [6]. Compounds 
which selectively deplete opioid receptor subtypes 
in vivo can allow one to perform direct observation 
of  the physiological effects associated with these 
receptor types [1]. 
We recently reported the synthesis o f  1S,2S- 
trans-2-isothiocyanato-N-methyl-N-[2-(1-pyrroli- 
dinyl)cyclohexyl]benzeneacetamide (1, f ig.l) [7], 
an electrophilic ligand for the x-opioid receptor in 
vitro. Although this compound could irreversibly 
inhibit x receptors with an ICso value of  100 nM, 
it failed to function as an irreversible inhibitor o f  
x-opioid receptors after intracerebroventricular 
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(ICV) injection [8]. A number of  factors, including 
the lower affinity of  1 for the x-opioid receptor 
compared with the parent molecule (U50,488) (2) 
(fig.l), could account for the inactivity of  this 
compound. in  vivo. A good site-directed affinity 
l igand should exhibit high affinity, specificity and 
reactivity towards the receptor with minimal reac- 
tivity towards water [1]. In our hands, the isothio- 
cyanate function has served this purpose well in a 
number of  studies [2,3,7,9]. 
Since the aromatic chlorine atoms on 2 have 
been identified as being important for high affinity 
and selectivity at the x-opioid receptor [10,11], we 
felt that 3a (an analog of  1 with the aromatic 
chlorine substituted as in 2) would have improved 
specificity for the x-opioid receptor compared with 
the dechloro compound,  1, and thus have a better 
chance of  functioning in vivo as a ~ receptor 
acylator. Since it has been well established that 
drug enantiomers can exert different, and in some 
cases opposite effects [12], it was imperative to 
synthesize both enantiomers of  (+)-3.  We report 
here the synthesis and characterization of an elec- 
trophilic ligand, 1S,2S-trans-2-isothiocyanato-4,5- 
dichloro -N -  methyl - N -  [2 - (I - pyrrolidinyl)cyclo - 
hexyl]benzeneacetamide (3a) as well as its enan- 
t iomer 3b and racemate (+)-3.  The 1S,2S enan- 
t iomer 3a bears the same stereochemical relation to 
the active enantiomer of  U50,488 (2). The optical 
purity of  3a and 3b follows from the previously 
demonstrated [13] optical purity of  the precursors 
4a and 4b. 
2. MATERIALS  AND METHODS 
2.1. Chemical synthesis 
The synthesis of (+)-3, 3a and 3b is shown in fig. 1. (IS,2S)- 
(+)-trans-2-Pyrrolidinyl-N-methylcyclohexylamine (4a) nd its 
enantiomer (4b) (fig. 1) were synthesized asdescribed [13]. Spec- 
tra from NMR (Varian XL300 spectrometer), infrared 
(Beckmann 3001 instrument), and chemical ionization (CI) 
mass pectroscopy (Finnegan Mat-311 spectrometer) were in ac- 
cord with the assigned structures. Gas chromatographic 
analysis (GC) was performed on a Hewlett-Packard 5880A in- 
strument with a carbowax capillary column and a flame ioniza- 
tion detector. Melting points were obtained using a 
Thomas-Hoover Unimelt apparatus, and are uncorrected. 
Specific rotation values were recorded at the sodium-D line us- 
ing a Perkin-Elmer 241 MC polarimeter. Thin-layer 
chromatographic analysis (TLC) was performed on Analtech 
silica gel (GHF) plates, elution being carried out with a solvent 
system consisting of chloroform/methanol/conc, ammonium 
hydroxide (90:9:1). All new compounds gave combustion 
analyses for carbon, hydrogen and nitrogen within ± 0.4% of 
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the calculated value and were performed at Atlanta Microlabs 
(Atlanta, GA). 
2.2. 2-Nitro-4,5-dichlorophenylacetic acid (5) 
To a stirred solution (at 0°C) of 3,4-dichlorophenylacetic 
acid (100 g, 0.488 mol) in a mixture of 200 ml fuming sulfuric 
acid (11 °70 SO3) and 300 ml acetic acid was added ropwise dur- 
ing a 10 min period, nitric acid [(90°7o; 1.5 equiv.) caution!], 
and the reaction mixture stirred at room temperature for a fur- 
ther 30 min at 20°C. The mixture was poured into ice-water 
(2000 ml), and the crystalline precipitate filtered and washed 
with 1000 ml distilled water. Recrystallization from 300 ml 
aqueous ethanol (1:1) afforded 66.1 g (54°/o) of 5 (m.p. 
130-132°C). 
2.3. (+_)-trans-2-Nitro-4,5-dichloro-N-methyl-N-[2-(1- 
pyrrolidinyl)cyclohexyl]benzeneacetamide [(+_)-6] 
To a stirred solution of (+)-4 (10.00g, 54.8 mmol), 5 
(14.89 g, 82.3 mmol) and dry pyridine (2.17 g, 27.4 mmol) in 
200 ml anhydrous methylene dichloride was added (in one por- 
tion), N,N-dicyclohexylcarbodiimide (22.63 g, 109.6 mmol) 
and the solution stirred for 10 min at 20°C or until TLC in- 
dicated that the reaction was complete. The precipitated N,N- 
dicyclohexylurea w s filtered and the solvent evaporated from 
the filtrate. The residue was partitioned between 500 ml of 10°70 
aqueous citric acid and ether (500 ml). The ether layer was 
discarded and the aqueous layer was washed with a further 2 × 
500 ml of ether, being then made alkaline by addition of excess 
aqueous concentrated ammonia solution. The alkaline solution 
was extracted with methylene dichloride (3 x 200 ml) and the 
organic extract dried by filtering through Na2SO4, the solvent 
being evaporated in vacuo. Treatment of crude 6 with a solution 
of HC1 gas in 2-propanol and crystallization of the salt from 
2-propanol (200 ml) afforded (+)-6.HCI [23.2 g, 94°70; m.p. 
259-260°C (dec.)]. 
2.4. 1S,2S-trans-2-Nitro-4,5-dichloro-N-methyl-N-[2-(1- 
pyrrolidinyOcyclohexyl]benzeneacetamide (6 ) 
10.00 g (54.8 mmol) of 4a [13] was coupled with 5 as de- 
scribed above and the HCI salt crystallized from 500 ml EtOAc 
to give 6a.HCI [(23.8 g, 96%), m.p. 239-240°C (dec.), 
[Ot']D - -  14 ° (c 0.74, MeOH)]. 
2.5. IR,2R-trans-2-Nitro-4,5-dichloro-N-methyI-N-[2-1- 
pyrrolidinyl)cyclohexyl]benzeneacetamide (6b) 
10.00 g (54.8 mmol) of 4b [13] was coupled with 5 as describ- 
ed above and the HCI salt recrystallized from 500 ml EtOAc to 
give 6b" HC1 [(22.8 g, 92070), m.p. 239-240°C (dec.), [OdD 12.7 °
(c 0.52, MeOH)I. 
2.6. ( + )-trans-2-Amino-4,5-dichloro-N-methyl-N-[2-(1- 
pyrrolidinyl)cyclohexyl]benzeneacetamide ff +_)-7] 
A solution of (+)-6-HC1 (16.00 g, 35.5 mmol) in a mixture 
of 95% ethanol (340 ml) and distilled water (110 ml) containing 
1.6 g PtO2 was stirred under an atmosphere of hydrogen for 
35 min at room temperature and atmospheric pressure. The 
catalyst was filtered through a pad of celite, and after evapora- 
tion of the solvent in vacuo, the product was crystallized from 
500 ml of hot 2-propanol to afford (+_)-7-HC1 [(9.60 g, 64%), 
m.p. 251-252°C (dec.)]. 
2.7. IS,2S-trans-2-Amino-4,5-dichloro-N-methyl-N-[2-(1- 
pyrrolidinyOcyclohexyl]benzeneacetamide (T ) 
A solution of 6a.HC1 (15.0g, 33.3 mmol) in methanol 
(100 ml) containing PtO2 (1.5 g) was stirred under an at- 
mosphere of hydrogen for 60 min at room temperature and at- 
mospheric pressure. The catalyst was filtered through a pad of 
celite and evaporation of the solvent left the product which was 
crystallized from 300 ml ethyl acetate to yield 7a. HCI [(10.8 g, 
77%), m.p. 185-188°C, [odd -25.6 ° (c 0.40, MeOH)]. 
2.8. IR,2R-trans-2-Amino-4,5-dichloro-N-methyl-N-[2-(1- 
pyrrolidinyl)cyclohexyl]benzeneacetamide (Tb) 
6b" HC1 (20.0 g, 44.4 mmol) was hydrogenated as described 
for 7a (section 2.7) and recrystallized from ethyl acetate to af- 
ford 7b. HC1 [(12.33 g, 66070), m.p. 185-189°C, [odn 23.1 ° (c 
0.55, MeOH)]. 
2.9. (+_)-trans-2-Isothiocyanato-4,5-dichloro-N-methyl-N- 
[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide [(+ )-3] 
(+)-7-HC1 (0.40 g, 0.95 mmol) was suspended in 100 ml dry 
chloroform and the solution acidified by addition of an excess 
of HCI gas dissolved in ethyl acetate (to diprotonate (+)-7). 
The solution was brought o reflux and a solution of 145/zl 
(I .90 mmol) of freshly redistilled thiophosgene (CSC12) in 5 ml 
dry chloroform was added in one portion. Refluxing was con- 
tinued for a further 20 min when TLC indicated that all of the 
starting material had reacted. The solvent and excess CSCI2 
were evaporated in vacuo to give a white crystalline residue 
(0.38 g, 86070). Crystallization of the HCI salt from 10 ml 
2-propanol afforded (+)-3. HCI [m.p. 230-231 °C (dec.)]. 
2.10. 1S,2S-trans-2-Isothiocyanato-4,5-dichloro-N-methyI-N- 
[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetarnide (3 ) 
7a'HCI (0.40 g, 0.95 mmol) was reacted with CSCI2 as 
described in section 2.9 for ( + )-7- HCI to afford 3a. HCI. This 
crystallized from 20 ml 2-propanol/ether, yielding 0.31 g (70°70) 
of 3a'HC1 [(m.p. 198-200°C (dec.), [a]D --48.3 ° (C 0.31, 
MeOH)]. 
2.11. 1R,2R-trans-2-Isothiocyanato-4,5-dichloro-N-methyl-N- 
[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide (3h) 
7b'HCI (0.40 g, 0.95 mmol) was reacted with CSC12 as 
described above and crystallized from 20 ml 2-propanol/ether 
to afford 0.27 g (61%) of 3b. HCI [m.p. 196-200 °C (dec.), [odo 
50.2 ° (c 0.41, MeOH)]. 
2.12. Binding assays and in vivo injection procedure 
In vitro x receptor binding assays were performed as in [15]. 
In vivo x receptor binding assays were carried out as follows: 
male Hartley guinea pigs weighing 300 g were anesthetized with 
halothane. Following placement in a stereotaxic apparatus, an 
incision was made through the neck muscles, exposing the oc- 
cipital membrane. A 10/zl Hamilton syringe used to deliver 
agents was inserted through the membrane into the cisterna 
magnum and 100 ,ug of various drugs, each dissolved in 10/zl 
dimethyl sulfoxide (DMSO) were injected. 24 h after injection, 
animals were decapitated and brain tissue immediately frozen in 
isopentane at - 80°C. The frozen tissue was later prepared for 
binding assay as described above [15]. All data were the results 
of duplicate xperiments, each performed in triplicate. 
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3. RESULTS 
Radioligand binding experiments with (+_)-3, 3a 
and 3b indicate that they are potent displacers of 
[3H]U69,593 and weak displacers of [aH]bremazo- 
cine (table 1), thus indicating ~- receptor subtype 
selectivity as has been observed previously for 1 
[7]. Compound 3a displaced [3H]U69,593 with an 
IC50 value of 25.92 + 0.36 nM, whereas 3b ex- 
hibited an IC5o value of 827.42 ___ 5.88 nM. These 
results are consistent with the enantioselectivity 
observed in vitro for the enantiomers of 2 [13]. In 
contrast to what was anticipated, the affinity of 3a 
was only marginally improved as compared with 1 
(table 1). 
Examination of ( +_ )-3 in vivo (ICV) showed that 
it had the capacity to deplete completely x-opioid 
receptors labelled by the x-opioid receptor ligand 
[3H]U69,593 [14] (table 2) while having no effect 
on/~ and ~ receptors [14]. Thus, ICV injection of 
100/zg (_+)-3 into guinea pigs resulted in 98o70 
depletion of x receptors labelled by [3H]U69,593, 
and 40O7o in the case of [3H]bremazocine; injection 
of 2 under the same conditions failed to affect any 
of the above receptor systems (not shown). The 
Table 1 
Displacement of x-opioid receptor radioligands by (+_)-3, 3a 
and 3b 
Compound IC50 (nM) 
[3H]U69,593 [3H]Bremazocine 
1 33.70 ± 0.82 270002 2601 
(±)-3 115.10 ± 1.23 10338 ± 1159 
3a 25.92 ± 0.36 5248 ± 398 
3b 827.42 ± 5.88 82624 ± 4866 
Table 2 
Effect of 100/zg intracerebroventricular injection of (+)-3 on 
[3H]U69,593 and [3H]bremazocine binding in guinea pig brain 
Compound Specific binding % of control 
(fmol/mg protein) 
Control 22.87 + 1.23 10o 
[3H]U69,593 0.32 + 0.30 1.30 ± 1.30 
Control 246.30 + 27.10 100 
[3H]Bremazocine 148.10 + 11.90 54.90 ± 4.43 
results for enantiomers 3a and 3b are included in 
a more extensive xamination of the in vivo acyla- 
tion of the x-opioid receptor by these and related 
compounds [14]. 
4. DISCUSSION 
Synthesis of 3a, 3b and (_+)-3 was successfully 
accomplished in three steps. It was hoped that 3a 
and (+)-3 would exhibit improved potency as 
acylators as compared to the previously report- 
ed 1S,2S-trans-2-isothiocyanato-N-methyl-N-[2- 
(1-pyrrolidinyl)cyclohexyl]benzeneacetamide (1, 
fig.l). The rationale for these compounds was a 
combination of the high-affinity ,vselective agonist 
U50,488 (2) and the lower affinity in vitro x recep- 
tor irreversible agent (1). In a previous tudy [15], 
2 displaced [3H]U69,593 with a Ki of 0.89 nM 
while its enantiomer exhibited a Ki of 299 nM. 3a 
showed only slightly improved affinity for the x- 
opioid receptor (IC5o = 25.92 _ 0.36 nM vs the 
value for 1 of 33.70 _+ 0.82 nM [4]; table 1). In a 
previous study [8], evaluation of 1 in vivo as a x, 
selective irreversible agent indicated that it was in- 
active. However, evaluation of the isothiocyanate 
derivative (+)-3 indicated that it was a potent and 
selective x receptor acylator in vivo. Increased 
reactivity of the isothiocyanate function of (+)-3 
towards nucleophiles as compared with 1 could be 
one factor accounting for the difference between 1
and 2 in vivo. The conclusion drawn here is that 
the isothiocyanate derivative (+)-3 is a valuable 
complement to 1 as a selective agent for in vivo in- 
hibition of x-opioid receptors. 
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